Showing results (2491-2500 of 2,573) with videos related to
Sort By:
Pageof 258
JTO Clinical and Research Reports|June 29, 2026
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY TrialNicolas Girard, Jonathan Goldman, Shun Lu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2016
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung CancerShirish M Gadgeel, Alice T Shaw, Ramaswamy Govindan, et al.Clinical Lung Cancer|August 29, 2022
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L StudyMyung J Ahn, Hye R Kim, James C H Yang, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 12, 2022
A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant womenBritt I Drögemöller, Galen E B Wright, Jessica Trueman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2020
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L TrialD Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.Breast Cancer Research : BCR|June 7, 2020
Enhanced mitochondrial fission suppresses signaling and metastasis in triple-negative breast cancerBrock A Humphries, Alyssa C Cutter, Johanna M Buschhaus, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II TrialDong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, et al.Nature Communications|June 11, 2016
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patientsJacob J Chabon, Andrew D Simmons, Alexander F Lovejoy, et al.Neuro-Oncology|June 28, 2022
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directionsAyal A Aizer, Nayan Lamba, Manmeet S Ahluwalia, et al.Nature Microbiology|July 29, 2024
Engineering Toxoplasma gondii secretion systems for intracellular delivery of multiple large therapeutic proteins to neuronsShahar Bracha, Hannah J Johnson, Nicole A Pranckevicius, et al.Pageof 258